Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 06, 2022 08:00 ET | Source: Crinetics Pharmaceuticals, Inc.

New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly

Open label extension data from investigational compound paltusotine orally presented at the 35th Brazilian Congress of Endocrinology and Metabolism Lowered and maintained IGF-1 at levels comparable...
March 30, 2022 16:01 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts

Results Further Support Clinical Proof-of-Concept for CRN04777 by Showing Dose-Dependent Decreases in Fasting and Sulfonylurea-Induced Insulin Secretion Management Hosting Webcast and Conference Call...
November 08, 2021 08:00 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress

SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
October 25, 2021 16:01 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
September 15, 2021 16:01 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals’ Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study

CRN04777 Phase 1 Program Progressing to Multiple Ascending Dose Cohorts to Advance Development as a Treatment for Congenital Hyperinsulinisms Demonstrated Dose-dependent Reductions in...
September 07, 2021 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals to Participate in September Investor Conferences

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel...
September 02, 2021 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Officer

SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
August 10, 2021 16:01 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study

CRN04894 Phase 1 Study Progressing to Multiple Ascending Dose Cohorts Management Hosting Webcast and Conference Call Today to Discuss Findings at 4:30 p.m. Eastern Time SAN DIEGO, Aug. 10,...
June 28, 2021 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly

- If successful, paltusotine would offer acromegaly patients a once-daily oral treatment option - SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a...
April 12, 2021 16:05 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Announces Closing of Common Stock Offering

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...

Next Page keyboard_arrow_right